Zenas BioPharma, Inc.
HealthcareNASDAQ:ZBIO · NASDAQ Global Select
+$2.04 today
Vol 1.32M · Avg 0.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-156.0%
avg -31.9%
ROIC
-65.6%
avg -88.5%
ROA
-98.5%
avg -88.8%
Analysis
ROIC is currently the strongest return metric at -65.6% versus its period average of -88.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Leon Oliver Moulder Jr. | Founder, CEO & Chairman | $891,800.00 | — | 69 | $96,928.00 | 0.22% |
Joseph L. Farmer | Chief Operating Officer & President | $877,500.00 | — | 54 | $175,000.00 | 0.39% |
Jennifer A. Fox | Chief Business Officer & Chief Financial Officer | $856,021.00 | — | 54 | $150,000.00 | 0.34% |
Lisa von Moltke | Head of Research & Development and Chief Medical Officer. | $759,567.00 | — | 67 | $400,000.00 | 0.90% |
Jeffrey Held | Chief Legal Officer | — | — | 57 | — | — |
Caroline Chevalier | Chief Administrative Officer | — | — | — | — | — |
Heinrich Schlieker | Chief Technical Officer | — | — | — | — | — |
Haley Laken | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
25
$29.05M
Sells
0
$0.00
Net Sentiment
+$29.05M
Net buying
Most Active
MOULDER LEON O JR
10 transactions
1–10 of 25
Analysis
Insiders reported 25 buys worth $29.05M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $29.05M. MOULDER LEON O JR was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +119.5% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +119.5% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Novavax, Inc.
NASDAQ:NVAX
$1.46B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Upstream Bio, Inc.
UPB
$331.96M
Who manages ZBIO?
Zenas BioPharma, Inc. (ZBIO) lists 8 active executives. The top listed executive is Joseph L. Farmer, Chief Operating Officer & President.
Are ZBIO insiders buying or selling?
Recent insider activity shows net buying of $46.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.